VCYT
Veracyte·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
VCYT Profile
Veracyte, Inc.
A genomic diagnostics company that develops and commercializes molecular diagnostic tests for cancer and other diseases
Healthcare Equipment and Supplies
08/15/2006
10/30/2013
NASDAQ Stock Exchange
824
12-31
Common stock
6000 Shoreline Court, Suite 300, South San Francisco, California 94080
--
Veracyte, Inc., was incorporated in Delaware on August 15, 2006 as Calderome Holding Company.
Calderome operated as a startup park until early 2008. On March 4, 2008, the company changed its name to Veracyte Ltd. Veracyte is a pioneering diagnostic company in the field of molecular cytology to improve patient outcomes and reduce healthcare costs. The company specializes in achieving accurate diagnoses for diseases that often require invasive procedures — diseases where costly interventions by many healthy patients ultimately prove unnecessary. The company obtains clinically actionable genomic information from the collection of cytological specimens in outpatient clinics, improving the accuracy of diagnosis in patient care at an earlier stage. The company's first commercial solution, Afirma thyroid FNA analysis, includes gene expression classification (GEC) at its core. GEC helps physicians reduce the number of unnecessary surgeries by employing proprietary 142 genetic markers to preoperatively determine whether thyroid nodules previously classified as indeterminate by cytopathology can be reclassified as benign. The company's operations are headquartered in South San Francisco, California and Austin, Texas and it operates in a division.
